Bank of America Securities analyst Jason Gerberry has reaffirmed his Buy rating on BioMarin Pharmaceutical (BMRN), setting a price target of $86.00. Gerberry, who focuses on the Healthcare sector and covers stocks like Merck & Company, Eli Lilly & Co, and Jazz Pharmaceuticals, has a strong track record according to TipRanks, with an average return of 18.5% and a 58.66% success rate on recommended stocks.
BioMarin Pharmaceutical has also received a Buy rating from BMO Capital’s David Lebowitz in a report issued on October 6. However, RBC Capital maintained a Hold rating on the stock. The company recently reported quarterly revenue of $989.71 million and a net profit of $44.76 million for the quarter ending June 30, compared to $825.41 million in revenue and a net profit of $240.53 million in the same period last year.
Despite positive analyst ratings, corporate insider sentiment for BioMarin Pharmaceutical is currently negative. Over the past quarter, there has been an increase in insiders selling their shares. Last month, George Eric Davis, the EVP and Chief Legal Officer of BMRN, sold 17,557 shares for a total of $1,163,677.96.